Year-round preventive treatment reduces malaria risk in young children

August 5, 2014
Credit: CDC

A year-round preventive drug treatment substantially reduces young children's risk of contracting malaria and poses no serious risk of adverse events, according to a study by researchers funded by the National Institutes of Health.

The findings demonstrate that prolonged treatment given from 6 to 24 months of age is safe and effective for young , according to the study authors. Year-round preventive measures are badly needed in locations like Uganda, where the study took place, and where malaria rates remain high throughout the year.

Most previous studies using drug treatment to prevent malaria have been limited to areas where there is only a seasonal risk of the disease, during the rainy season, when most malaria episodes in children occur. In those studies, preventive drug treatment was given for only a few months at most. The current study demonstrated that continuous preventive treatment can substantially reduce to infants, who are at greatest risk of and death.

The study was conducted by Grant Dorsey, M.D., of the University of California, San Francisco (UCSF) at San Francisco General Hospital, with colleagues from UCSF and the Infectious Diseases Research Collaboration, Kampala, Uganda, and Makerere University College of Health Sciences, also in Kampala. The researchers published their findings online in PLOS Medicine.

"This study has identified an effective measure for reducing the incidence of malaria in children living in an area with high rates of the disease," said Lynne Mofenson, M.D., chief of the Maternal and Pediatric Infectious Disease Branch at the NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which provided funding for the study.

Dr. Mofenson said malaria poses a greater threat to children below 3 years of age than to older children. Malaria in children under age 3 is more likely to be fatal than in . In younger children, also, the disease may affect the brain and either prove fatal or result in brain damage.

"It's better to try to prevent a potentially fatal illness than it is to wait until the child gets the illness and is at increased risk for dying," Dr. Mofenson added. Older children are considered to be less at risk from malaria because they tend to develop natural immunity against the disease as they get older.

The researchers found that a monthly dose of dihydroartemisinin-piperaquine (DP) was the most effective of three anti-malaria drugs at reducing malaria risk in children from 6 months to 24 months of age. The other two study drugs— monthly sulfadoxine-pyrethamine (SP) or daily trimethoprim-sulfamethoxozole (TS)— have been in use longer, and in many locations the malaria-causing parasite has developed a resistance to them. The researchers conducted the study to determine if the benefits of treatment outweighed the potential risk of anemia and other side effects from the drugs.

"When you're giving drugs to prevent the disease, you have a much higher bar for safety," Dr. Dorsey said. "When the drugs are given longer term, you may have an increased risk of side effects to contend with."

Beginning at age 6 months, 393 children from Tororo, Uganda were randomized to one of four groups: monthly DP, monthly SP, or daily TS, or to a control group, which did not receive any preventive drug treatment—which is the standard medical practice in the area. Insecticide-treated mosquito bed nets are a mainstay for reducing the spread of malaria, and all of the families were given nets to put over the children when they slept. By 24 months of age, 352 children were still taking part in the study.

The researchers calculated the study results in terms of a numerical unit known as person years, which takes into account the number of individuals participating in the study and the time each person took part. (A study following 1,000 people for 1 year would contain 1,000 person years of data.) For the children in the DP group, there were 3.02 malaria episodes per person year, 5.21 for the TS group, 6.73 for the SP group, and 6.95 for the control group. Compared to the , children in the DP group were 58 percent less likely to develop malaria. Between the groups, there was no difference in rates of anemia and other adverse events that have been associated with the drugs used in the study.

After discontinuing the study drugs at age 24 months, the researchers followed the children until age 3 and found no difference in malaria rates between the groups. According to the study authors, the findings help to allay any concerns resulting from earlier studies that continuous drug treatment might interfere with the children's ability to develop an immune response against malaria, and so make them more likely to get the disease after treatment stops.

"Our study showed that preventive can greatly reduce malaria in in areas where there are year round high rates of transmission," Dr. Dorsey said. "We believe that this treatment regimen will be of substantial benefit in many parts of the world in need of improved control measures."

Explore further: Malaria severity not determined solely by parasite levels in blood

More information: Bigira V, Kapisi J, Clark TD, Kinara S, Mwangwa F, et al. (2014) Protective Efficacy and Safety of Three Antimalarial Regimens for the Prevention of Malaria in Young Ugandan Children: A Randomized Controlled Trial. PLoS Med 11(8): e1001689. doi:10.1371/journal.pmed.1001689. … journal.pmed.1001689

Related Stories

Malaria severity not determined solely by parasite levels in blood

May 7, 2014
Although malaria kills some 600,000 African children each year, most cases of the mosquito-borne parasitic disease in children are mild. Repeated infection does generate some immunity, and episodes of severe malaria are unusual ...

Malaria vaccine shows continued protection during 18 months of follow-up

July 29, 2014
A vaccine previously shown to reduce malaria in young infants and children reduces larger numbers of malaria cases in areas of higher malaria transmission, according to results from an ongoing clinical trial published in ...

GSK asks European regulator to OK malaria shot

July 24, 2014
(AP)—Pharma giant GSK said Thursday it is submitting its malaria vaccine for regulatory approval to the European Medicines Agency.

HIV treatment reduces risk of malaria recurrence in children, study shows

November 28, 2012
A combination of anti-HIV drugs has been found to also reduce the risk of recurrent malaria by nearly half among HIV-positive children, according to researchers supported by the National Institutes of Health.

Increasing malarial drug resistance a growing threat

July 31, 2014
(HealthDay)—The parasite that causes malaria is growing increasingly resistant to the drugs commonly used to fight it, according to new surveillance reports. But several new drugs are in development, and at least one in ...

Rectal artesunate beneficial in young children with severe malaria, but may be harmful in older children, adults

May 30, 2014
Researchers from the Cochrane Infectious Diseases Group, hosted at LSTM, conducted an independent review of the effects of pre-referral rectal artesunate for people with severe malaria, published in the Cochrane Library today.

Recommended for you

Faulty gene linked to obesity in adults

August 18, 2017
Groundbreaking new research linking obesity and metabolic dysfunction to a problem in the energy generators in cells has been published by researchers from the Harry Perkins Institute of Medical Research and The University ...

Two lung diseases killed 3.6 million in 2015: study

August 17, 2017
The two most common chronic lung diseases claimed 3.6 million lives worldwide in 2015, according to a tally published Thursday in The Lancet Respiratory Medicine.

New test differentiates between Lyme disease, similar illness

August 16, 2017
Lyme disease is the most commonly reported vector-borne illness in the United States. But it can be confused with similar conditions, including Southern Tick-Associated Rash Illness. A team of researchers led by Colorado ...

Addressing superbug resistance with phage therapy

August 16, 2017
International research involving a Monash biologist shows that bacteriophage therapy – a process whereby bacterial viruses attack and destroy specific strains of bacteria - can be used successfully to treat systemic, multidrug ...

Can previous exposure to west Nile alter the course of Zika?

August 15, 2017
West Nile virus is no stranger to the U.S.-Mexico border; thousands of people in the region have contracted the mosquito-borne virus in the past. But could this previous exposure affect how intensely Zika sickens someone ...

Compounds in desert creosote bush could treat giardia and 'brain-eating' amoeba infections

August 15, 2017
Researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego and the University of Colorado Anschutz Medical Campus have found that compounds produced by the creosote bush, a ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.